Equities research analysts expect BioScrip Inc (NASDAQ:BIOS) to post ($0.11) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioScrip’s earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.08). BioScrip reported earnings per share of ($0.16) during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The business is scheduled to announce its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.31) to ($0.21). For the next year, analysts anticipate that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.18) to ($0.14). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow BioScrip.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, March 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The business had revenue of $182.50 million during the quarter, compared to analysts’ expectations of $171.35 million. During the same quarter last year, the company posted ($0.06) earnings per share. The business’s quarterly revenue was down 24.0% on a year-over-year basis.
NASDAQ:BIOS traded down $0.09 during trading hours on Monday, hitting $2.55. 1,068,632 shares of the stock were exchanged, compared to its average volume of 960,268. BioScrip has a twelve month low of $1.35 and a twelve month high of $3.39. The company has a debt-to-equity ratio of -5.65, a quick ratio of 1.42 and a current ratio of 1.79. The company has a market cap of $337.12, a price-to-earnings ratio of -5.80 and a beta of 0.11.
Several hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC acquired a new position in shares of BioScrip in the 4th quarter valued at $174,000. Gotham Asset Management LLC acquired a new position in shares of BioScrip in the 4th quarter valued at $114,000. Two Sigma Advisers LP lifted its stake in shares of BioScrip by 100.4% in the 4th quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after purchasing an additional 64,238 shares during the period. Royce & Associates LP lifted its stake in shares of BioScrip by 942.6% in the 4th quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after purchasing an additional 1,649,500 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of BioScrip by 10.2% in the 4th quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after purchasing an additional 611,302 shares during the period. 84.29% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “BioScrip Inc (BIOS) Expected to Post Earnings of -$0.11 Per Share” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3344035/bioscrip-inc-bios-expected-to-post-earnings-of-0-11-per-share.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.